Plain-English translation of NCT07281521 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing the CardioWave Pulsed Field Ablation System — a new catheter-based procedure that uses electrical energy to treat persistent atrial fibrillation (a condition where your heart beats irregularly for long periods). The study will enroll up to 200 patients across 4 hospitals in Europe to see whether this treatment is safe and effective for people whose irregular heartbeat hasn't responded well to medication.
Many people with persistent atrial fibrillation don't respond well to anti-arrhythmic drugs or cannot tolerate their side effects. This trial exists to evaluate whether this new energy-based catheter approach can safely and effectively restore normal heart rhythm in these patients.
If you're enrolled, you will come to the hospital for a catheter ablation procedure using the new CardioWave Pulsed Field Ablation System. The catheter is guided through blood vessels to your heart, where it uses electrical energy to treat the areas causing irregular heartbeats. Depending on which phase of the trial you join, you may have follow-up visits and heart monitoring for up to 12 months after the procedure to check your progress and look for any side effects.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Croatia
Czechia
Sponsor
CardioFocus
Enrollment target
~200 participants
Started
February 2023
Primary completion
August 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in August 2026.